A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays

Journal of Virology

Volumn 86, Issue 22, 2012, Pages 12039-12052

  Alpert, Michael D ^a   Heyer, Lisa N ^a   Williams, David E J ^a   Harvey, Jackson D ^a   Greenough, Thomas ^b   Allhorn, Maria ^c   Evans, David T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; LUCIFERASE;

ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOASSAY; IMMUNOREACTIVITY; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REPRODUCIBILITY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MACACA; NEUTRALIZATION TESTS; PROTEIN BINDING; RECEPTORS, IGG; REPRODUCIBILITY OF RESULTS; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84869110634     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01650-12     Document Type: Article

References (145)

1. Ackerman ME, et al. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366:8-19.
2. Allhorn M, et al. 2010. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood 115:5080-5088.
3. Allhorn M, Olin AI, Nimmerjahn F, Collin M. 2008. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 3:e1413. doi:10.1371/journal.pone.0001413.
4. Alpert MD, et al. 2010. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. J. Virol. 84:10748-10764.
5. Alter G, Moody MA. 2010. The humoral response to HIV-1: new insights, renewed focus. J. Infect. Dis. 202(Suppl 2):S315-S322.
6. Alter G, et al. 2006. Low perforin and elevated SHIP-1 expression is associated with functional anergy of natural killer cells in chronic HIV-1 infection. AIDS 20:1549-1551.
7. Alter G, et al. 2005. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106:3366-3369.
8. Anonymous. 1996. Guide for the care and use of laboratory animals, p 86-123. National Academy Press, Washington, DC.
9. Baine I, Abe BT, Macian F. 2009. Regulation of T-cell tolerance by calcium/NFAT signaling. Immunol. Rev. 231:225-240.
10. Barouch DH, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
11. Bou-Habib DC, et al. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
12. Broder CC, et al. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 91: 11699-11703.
13. Bruhns P, et al. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716-3725.
14. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H. 2007. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J. Virol. 81:525-531.
15. Burton DR, et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
16. Chen B, et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
17. Chen L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127.
18. Choe H, et al. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
19. Chung AW, et al. 2011. Immune escape from HIV-specific antibodydependent cellular cytotoxicity (ADCC) pressure. Proc. Natl. Acad. Sci. U. S. A. 108:7505-7510.
20. Chung AW, et al. 2011. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 24:171-175.
21. Chung AW, et al. 2011. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 58:127-131.
22. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. 2009. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182:1202-1210.
23. Cocchi F, et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
24. Cohen J. 1994. The HIV vaccine paradox. Science 264:1072-1074.
25. Cohen J. 1993. Jitters jeopardize AIDS vaccine trials. Science 262:980-981.
26. Cole KS, et al. 2001. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 290:59-73.
27. Collin M, Olsen A. 2001. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 20:3046-3055.
28. Cooper MA, Fehniger TA, Caligiuri MA. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
29. Cranage MP, et al. 1993. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 9:13-22.
30. Daar ES, Li XL, Moudgil T, Ho DD. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U. S. A. 87: 6574-6578.
31. Deng H, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
32. Desrosiers R.C. 1999. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat. Med. 5:723-725.
33. Dragic T, et al. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
34. Earl PL, et al. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
35. Evans DT, Bricker JE, Desrosiers R.C. 2004. A novel approach for producing lentiviruses that are limited to a single cycle of infection. J. Virol. 78:11715-11725.
36. Evans DT, Desrosiers R.C. 2001. Immune evasion strategies of the primate lentiviruses. Immunol. Rev. 183:141-158.
37. Fauci AS, Mavilio D, Kottilil S. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5:835-843.
38. Ferrari G, et al. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a commonADCCepitope in human HIV-1 serum. J. Virol. 85:7029-7036.
39. Florese RH, et al. 2009. Contribution of nonneutralizing vaccineelicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 182:3718-3727.
40. Florese RH, et al. 2006. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 177:4028-4036.
41. Flynn NM, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
42. Foreman KE, et al. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1147-1155.
43. Forthal DN, Gilbert PB, Landucci G, Phan T. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
44. Forthal DN, et al. 2006. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80:9217-9225.
45. Forthal DN, Landucci G, Daar ES. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75:6953-6961.
46. Fouda GG, et al. 2011. HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J. Virol. 85:9555-9567.
47. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore J.P. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
48. Fouts TR, Trkola A, Fung MS, Moore J.P. 1998. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS Res. Hum. Retroviruses 14: 591-597.
49. Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221:35-41.
50. Goldstein S, et al. 1994. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J. Med. Primatol. 23:75-82.
51. Gomez-Roman VR, et al. 2006. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308:53-67.
52. Gomez-Roman VR, et al. 2006. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody- dependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune Defic. Syndr. 43:270-277.
53. Gomez-Roman VR, et al. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:2185-2189.
54. Gorny MK, Zolla-Pazner S. 2003. Human monoclonal antibodies that neutralize HIV-1, p 37-51. LA-UR 04-8162. In Korber BTM, Brander C, Haynes BF, Koup R, Moore J.P, Walker BD, Watkins DI (ed), HIV immunology and HIV/SIV vaccine databases 2003. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM.
55. Guidotti LG, Chisari FV. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91.
56. Guo RF, Ward PA. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23:821-852.
57. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
58. Hessell AJ, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
59. Hidajat R, et al. 2009. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83:791-801.
60. Howell DN, Andreotti PE, Dawson JR, Cresswell P. 1985. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J. Immunol. 134:971-976.
61. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. 2011. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412:110-116.
62. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144:16-22.
63. Jia B, et al. 2009. Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIVmac239. PLoS Pathog. 5:e1000272. doi:10.1371/journal.ppat.1000272.
64. Johansson SE, et al. 2011. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol. 24:359-368.
65. Johnson WE, Desrosiers R.C. 2002. Viral persistance: HIV's strategies of immune system evasion. Annu. Rev. Med. 53:499-518.
66. Johnson WE, et al. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77:9993-10003.
67. Kantakamalakul W, et al. 2006. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediatedcytotoxicity (ADCC) activity in HIV-1 infected individuals. J. Immunol. Methods 315:1-10.
68. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
69. Koch M, et al. 2003. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387-400.
70. Kottilil S, et al. 2003. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187:1038-1045.
71. Koup RA, et al. 1989. Antigenic specificity of antibody-dependent cellmediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J. Virol. 63:584-590.
72. Kwong PD, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
73. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
74. Labrijn AF, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565.
75. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. 1986. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136:4480-4486.
76. Larman MG, Sheehan CB, Gardner DK. 2006. Calcium-free vitrification reduces cryoprotectant-induced zona pellucida hardening and increases fertilization rates in mouse oocytes. Reproduction 131:53-61.
77. Li Y, et al. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65:3973-3985.
78. Lozada C, et al. 1995. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc. Natl. Acad. Sci. U. S. A. 92:8378-8382.
79. Macian F, et al. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109:719-731.
80. Mascola JR, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340-348.
81. Mavilio D, et al. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. U. S. A. 100:15011-15016.
82. Mavilio D, et al. 2005. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. U. S. A. 102:2886-2891.
83. Means R.E, Greenough T, Desrosiers R.C. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:7895-7902.
84. Miller CJ, et al. 2007. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J. Virol. 81:5024-5035.
85. Mitchell WM, Forti RL, Vogler LB, Lawton AR, Gregg CR. 1983. Spontaneous and interferon resistant natural killer cell anergy in AIDS. AIDS Res. 1:221-229.
86. Montefiori D, et al. 2007. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4:e348. doi:10.1371/journal.pmed.0040348.
87. Moore J.P, et al. 1993. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses 9:529-539.
88. Moore J.P, et al. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
89. Moore J.P, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
90. Morris MA, Ley K. 2004. Trafficking of natural killer cells. Curr. Mol. Med. 4:431-438.
91. Myers G, Lenroot R. 1992. HIV glycosylation: what does it portend? AIDS Res. Hum. Retroviruses 8:1459-1460.
92. Myszka DG, et al. 2000. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U. S. A. 97:9026-9031.
93. Nataf S, Davoust N, Ames RS, Barnum SR. 1999. Human T cells express the C5a receptor and are chemoattracted to C5a. J. Immunol. 162:4018-4023.
94. Nimmerjahn F, Ravetch JV. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
95. Nitayaphan S, et al. 2004. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190:702-706.
96. O'Doherty U, Swiggard WJ, Malim MH. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:10074-10080.
97. Oh-hora, M, Rao A. 2008. Calcium signaling in lymphocytes. Curr. Opin. Immunol. 20:250-258.
98. Oliva A, et al. 1998. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CCchemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102:223-231.
99. Ottonello L, et al. 1999. rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J. Immunol. 162:6510-6517.
100. Parren PW, Burton DR, Sattentau QJ. 1997. HIV-1 antibody-debris or virion? Nat. Med. 3:366-367.
101. Patterson LJ, et al. 2008. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 374:322-337.
102. Pikora C, Wittish C, Desrosiers R.C. 2005. Identification of two Nlinked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J. Virol. 79:12575-12583.
103. Pitisuttithum P, et al. 2006. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
104. Pollara J, et al. 2011. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79: 603-612.
105. Pugach P, et al. 2004. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321:8-22.
106. Putkonen P, et al. 1993. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. J. Med. Primatol. 22:100-103.
107. Reeves RK, et al. 2010. CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood 115:4439-4446.
108. Reitter JN, Means R.E, Desrosiers R.C. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-684.
109. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. 2006. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 20: 1471-1479.
110. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
111. Roben P, et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
112. Rook AH, et al. 1987. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J. Immunol. 138:1064-1067.
113. Rot A, von Andrian UH. 2004. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22:891-928.
114. Salazar-Gonzalez JF, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
115. Sattentau QJ, Moore J.P. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
116. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
117. Schwartz RH. 2003. T cell anergy. Annu. Rev. Immunol. 21:305-334.
118. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
119. Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
120. Spear GT, Landay AL, Sullivan BL, Dittel B, Lint TF. 1990. Activation of complement on the surface of cells infected by human immunodeficiency virus. J. Immunol. 144:1490-1496.
121. Spear GT, Sullivan BL, Landay AL, Lint TF. 1990. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J. Virol. 64:5869-5873.
122. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
123. Stott EJ. 1991. Anti-cell antibody in macaques. Nature 353:393.
124. Sun Y, et al. 2011. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85: 6906-6912.
125. Tanneau F, et al. 1990. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibodydependent cellular cytotoxicity in vivo. J. Infect. Dis. 162:837-843.
126. Tarazona R, et al. 2002. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J. Clin. Immunol. 22:176-183.
127. Thongcharoen P, et al. 2007. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/ LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46:48-55.
128. Trkola A, et al. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
129. Trkola A, Matthews J, Gordon C, Ketas T, Moore J.P. 1999. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 73:8966-8974.
130. Tyler DS, et al. 1989. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J. Immunol. 142:1177-1182.
131. von Andrian UH, Mackay CR. 2000. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343:1020-1034.
132. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
133. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
134. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48.
135. Wu L, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
136. Wyatt R, et al. 1997. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J. Virol. 71:9722-9731.
137. Wyatt R, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
138. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
139. Xiao P, et al. 2010. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84:7161-7173.
140. Yagita M, et al. 2000. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922-930.
141. Yang X, et al. 2000. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74:4746-4754.
142. Yang X, Kurteva S, Lee S, Sodroski J. 2005. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79: 3500-3508.
143. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. 2005. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79:12132-12147.
144. Yuste E, et al. 2008. Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J. Virol. 82:12472-12486.
145. Zwick M.B, Burton DR. 2007. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr. HIV Res. 5:608-624.